| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
Isotope-labeled compounds act as tracers for quantitation during drug development; however, DL-Aspartic acid itself does not possess a defined pharmacological target.
|
|---|---|
| ln Vitro |
Drug compounds have included stable heavy isotopes of carbon, hydrogen, and other elements, mostly as quantitative tracers while the drugs were being developed. Because deuteration may have an impact on a drug's pharmacokinetics and metabolic profile, it has drawn attention [1].
Stable heavy isotopes are incorporated into drug molecules primarily as tracers for quantitation; directly measured IC50/EC50 values for this specific labeled compound are not available. |
| ln Vivo |
No dedicated in vivo efficacy studies exist for the labeled variant; unlabeled DL-Aspartic acid is an endogenous amino acid involved in the urea cycle and neurotransmission.
|
| Enzyme Assay |
Isotope-labeled compounds are quantified via LC-MS/MS; samples are spiked with internal standard, proteins precipitated, and supernatant analyzed on a C18 column with MRM detection.
|
| Cell Assay |
The compound is dissolved at 10 mM in DMSO and diluted in cell medium to working concentrations (0.1-100 microM) for uptake studies; cells are lysed and intracellular isotope enrichment is measured.
|
| Animal Protocol |
Typically administered intravenously at 1-10 mg/kg in saline or DMSO/PEG formulation; blood is collected at timed intervals and plasma analyzed for isotope-labeled drug content.
|
| ADME/Pharmacokinetics |
PK properties of the labeled compound are expected to match unlabeled DL-Aspartic acid; however, direct PK data for this specific product is not available in literature.
|
| Toxicity/Toxicokinetics |
DL-Aspartic acid is naturally occurring and generally recognized as safe at physiological levels; however, high-dose toxicity studies for this specific labeled product are not available.
|
| References | |
| Additional Infomation |
This product is an analytical standard for LC-MS method validation and metabolic flux analysis; it is not a pharmaceutical drug and has no clinical trial or marketing approval status.
|
| Molecular Formula |
C313CH8CL15NO4
|
|---|---|
| Molecular Weight |
171.55
|
| Related CAS # |
DL-Aspartic acid-13C;137168-39-9;DL-Aspartic acid-13C,15N;98532-13-9;DL-Aspartic acid-3-13C;202326-56-5;DL-Aspartic acid-13C1;68315-35-5
|
| Appearance |
White to off-white solid powder
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: (1). This product requires protection from light (avoid light exposure) during transportation and storage. (2). Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO :~50 mg/mL (~291.46 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 5 mg/mL (29.15 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 5 mg/mL (29.15 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 50.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 5 mg/mL (29.15 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 5.8292 mL | 29.1460 mL | 58.2920 mL | |
| 5 mM | 1.1658 mL | 5.8292 mL | 11.6584 mL | |
| 10 mM | 0.5829 mL | 2.9146 mL | 5.8292 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
